Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B5a177f0f49cd85acb908de0de8b7af4a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B5a177f0f49cd85acb908de0de8b7af4a NCIT_P378 "NCI" @default.
- B5a177f0f49cd85acb908de0de8b7af4a type Axiom @default.
- B5a177f0f49cd85acb908de0de8b7af4a annotatedProperty IAO_0000115 @default.
- B5a177f0f49cd85acb908de0de8b7af4a annotatedSource NCIT_C172197 @default.
- B5a177f0f49cd85acb908de0de8b7af4a annotatedTarget "A preparation of autologous T-lymphocytes genetically engineered with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-FLT3 CAR T cells AMG 553 target and bind to tumor cells expressing FLT3, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of FLT3-expressing tumor cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs)." @default.